Boceprevir for COVID-19
Boceprevir has been reported as potentially beneficial for early treatment of COVID-19. We have not reviewed these studies. See all other treatments.
Potential clinical drugs as covalent inhibitors of the priming proteases of the spike protein of SARS-CoV-2, Computational and Structural Biotechnology Journal, doi:10.1016/j.csbj.2020.08.016 ,
Artificial intelligence approach fighting COVID-19 with repurposing drugs, Biomedical Journal, doi:10.1016/j.bj.2020.05.001 ,
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents, Communications Biology, doi:10.1038/s42003-020-01577-x ,
Potential inhibitors of SARS-CoV-2: recent advances, Journal of Drug Targeting, doi:10.1080/1061186X.2020.1853736 ,
Virtual Screening of Substances Used in the Treatment of SARS-CoV-2 Infection and Analysis of Compounds With Known Action on Structurally Similar Proteins From Other Viruses, Biomedicine & Pharmacotherapy, doi:10.1016/j.biopha.2022.113432 ,
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.